Peter J Hosein1, Ana Echenique2, Arturo Loaiza-Bonilla3, Tatiana Froud2, Katuzka Barbery2, Caio M Rocha Lima2, Jose M Yrizarry2, Govindarajan Narayanan2. 1. Department of Medicine and Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave., Suite 3400, Miami, FL 33136. Electronic address: phosein@med.miami.edu. 2. Department of Radiology and Division of Vascular/Interventional Radiology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave., Suite 3400, Miami, FL 33136. 3. Department of Medicine and Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave., Suite 3400, Miami, FL 33136.
Abstract
PURPOSE: To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). MATERIALS AND METHODS: A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. RESULTS: Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. CONCLUSIONS: Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.
PURPOSE: To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). MATERIALS AND METHODS: A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. RESULTS: Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. CONCLUSIONS: Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.
Authors: Russell C Langan; Debra A Goldman; Michael I D'Angelica; Ronald P DeMatteo; Peter J Allen; Vinod P Balachandran; William R Jarnagin; T Peter Kingham Journal: J Surg Oncol Date: 2017-05-11 Impact factor: 3.454
Authors: Alette H Ruarus; Laurien G P H Vroomen; Robbert S Puijk; Hester J Scheffer; Theo J C Faes; Martijn R Meijerink Journal: Cardiovasc Intervent Radiol Date: 2018-04-23 Impact factor: 2.740
Authors: Hester J Scheffer; Laurien G P H Vroomen; Karin Nielsen; Aukje A J M van Tilborg; Emile F I Comans; Cornelis van Kuijk; Bram B van der Meijs; Janneke van den Bergh; Petrousjka M P van den Tol; Martijn R Meijerink Journal: BMC Cancer Date: 2015-10-24 Impact factor: 4.430
Authors: Andreas Schicho; Christoph Niessen; Michael Haimerl; Isabel Wiesinger; Christian Stroszczynski; Lukas P Beyer; Philipp Wiggermann Journal: Cancer Manag Res Date: 2018-12-27 Impact factor: 3.989